The inhibition of Pseudomonas aeruginosa biofilm formation by micafungin and the enhancement of antimicrobial agent effectiveness in BALB/c mice
| dc.contributor.author | Kissoyan, Kohar Annie B. | |
| dc.contributor.author | Bazzi, Wael | |
| dc.contributor.author | Hadi, Usamah Moh D. | |
| dc.contributor.author | Matar, Ghassan | |
| dc.contributor.department | Experimental Pathology, Microbiology, and Immunology | |
| dc.contributor.department | Otolaryngology/Head and Neck Surgery | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:38:55Z | |
| dc.date.available | 2025-01-24T11:38:55Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | Abstract: Micafungin inhibits biofilm formation by impeding 1,3-β-D-glucan synthesis in Candida albicans. Since Pseudomonas aeruginosa also has 1,3-β-D-glucan in its cell wall, this study assessed the effects of antibacterial agents in vitro and in vivo on micafungin-treated biofilm-forming P. aeruginosa isolates. After treatment with micafungin as well as with a panel of four antibacterial agents, biofilm production was significantly reduced as measured by spectrophotometry. The relative mRNA transcription levels for the genes encoding pellicles (pelC) and cell wall 1,3-β-D-glucan (ndvB), which were measured by quantitative reverse transcription PCR (qRT-PCR), significantly decreased with micafungin treatment. In vivo, the survival rates of P. aeruginosa-infected BALB/c mice significantly increased after combined treatment with micafungin and each of the antibacterial agents. Of these treatments, the combination of micafungin with levofloxacin had the highest survival rate; this combination was the most effective treatment against P. aeruginosa-induced infection. © 2016 Informa UK Limited, trading as Taylor & Francis Group. | |
| dc.identifier.doi | https://doi.org/10.1080/08927014.2016.1199021 | |
| dc.identifier.eid | 2-s2.0-84979074123 | |
| dc.identifier.pmid | 27347641 | |
| dc.identifier.uri | http://hdl.handle.net/10938/29105 | |
| dc.language.iso | en | |
| dc.publisher | Taylor and Francis Ltd. | |
| dc.relation.ispartof | Biofouling | |
| dc.source | Scopus | |
| dc.subject | Antibacterial agents | |
| dc.subject | Balb/c mice | |
| dc.subject | Biofilm | |
| dc.subject | Micafungin | |
| dc.subject | Pseudomonas aeruginosa | |
| dc.subject | Animals | |
| dc.subject | Anti-bacterial agents | |
| dc.subject | Beta-glucans | |
| dc.subject | Biofilms | |
| dc.subject | Candida albicans | |
| dc.subject | Drug therapy, combination | |
| dc.subject | Echinocandins | |
| dc.subject | Levofloxacin | |
| dc.subject | Lipopeptides | |
| dc.subject | Male | |
| dc.subject | Mice | |
| dc.subject | Mice, inbred balb c | |
| dc.subject | Pseudomonas infections | |
| dc.subject | Survival analysis | |
| dc.subject | Mus | |
| dc.subject | Antiinfective agent | |
| dc.subject | Beta glucan | |
| dc.subject | Beta-1,3-glucan | |
| dc.subject | Echinocandin | |
| dc.subject | Lipopeptide | |
| dc.subject | Antimicrobial activity | |
| dc.subject | Bacterium | |
| dc.subject | Cells and cell components | |
| dc.subject | Drug | |
| dc.subject | Rodent | |
| dc.subject | Spectrophotometry | |
| dc.subject | Survival | |
| dc.subject | Animal | |
| dc.subject | Antagonists and inhibitors | |
| dc.subject | Bagg albino mouse | |
| dc.subject | Combination drug therapy | |
| dc.subject | Drug effects | |
| dc.subject | Growth, development and aging | |
| dc.subject | Microbiology | |
| dc.subject | Mouse | |
| dc.subject | Physiology | |
| dc.title | The inhibition of Pseudomonas aeruginosa biofilm formation by micafungin and the enhancement of antimicrobial agent effectiveness in BALB/c mice | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1